Mcurextx
2 known investors
mCureX Therapeutics is a South Korean pre-clinical biotech developing next-generation mRNA therapeutics and vaccines.
Also known as mCureX · mCureX Therapeutics
Investors · 2
Company profile
researched Aug 2026mCureX Therapeutics is a biotechnology company based in Seongnam, Gyeonggi Province, South Korea, that develops next-generation mRNA therapeutics and vaccines. Its work spans genetic diseases, infectious diseases and cancer, and its gene editing activity centers on CRISPR-Cas9 delivered via mRNA. The company is a subsidiary of OliX Therapeutics.
The company is at the pre-clinical stage and maintains a published R&D pipeline. It is privately funded.
Latest developments
In 2022 the company announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing for genetic eye diseases.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a pre-clinical mRNA therapeutics developer and a subsidiary of OliX Therapeutics, working in genetic disease, infectious disease and oncology indications.
Technology
The company's platform is built around next-generation mRNA therapeutics and vaccines, including mRNA-based delivery of CRISPR-Cas9 genome editing components.
Go-to-market
Patients with genetic diseases, infectious diseases and cancer, addressed through therapeutic and vaccine programs.
Geography
Headquartered in Seongnam, Gyeonggi, South Korea.
History
The company operates as a subsidiary of OliX Therapeutics. Sangwook Lee, previously a researcher in the Ota Lab until 2024, serves as Chief Technology Officer.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsmCureX Therapeutics announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing for the treatment of genetic eye diseases.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Company: mCureX Therapeuticscrisprmedicinenews.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mcurextx do?
- mCureX Therapeutics is a South Korean pre-clinical biotech developing next-generation mRNA therapeutics and vaccines.
- Who are Mcurextx's investors?
- Mcurextx's investors include Aju IB Invesment Corporation, Kiwoom Investment.